Market Place
Sourcing Support
TransThera Announces Ph I Result of TT-01488 in B-cell Malignancies
10 Dec 2024 //
PR NEWSWIRE
TransThera Announces Tinengotinib + Atezolizumab Data in BTC
09 Dec 2024 //
PR NEWSWIRE
TransThera Announced Phase 3 Trial for Cholangiocarcinoma Authorized in EU
08 Mar 2024 //
PR NEWSWIRE
TransThera initiates IND-Enabling studies for TT-02332
26 Feb 2024 //
PR NEWSWIRE
TransThera Announces Phase 3 Completed First Patient Dosing Evaluating Tinengotinib
21 Dec 2023 //
PR NEWSWIRE
TransThera announces an oral presentation of tinengotinib data in breast cancer
07 Dec 2023 //
PR NEWSWIRE
TransThera announces two oral presentations of tinengotinib clinical data
09 Oct 2023 //
PR NEWSWIRE
FDA approves TransThera’s IND application for B-Cell lymphoma treatment
22 Feb 2022 //
PHARMACEUTICAL-TECHNOLOGY
NMPA Accepts and FDA Approves TransThera`s IND of TT-01488 for B-Cell Lymphomas
18 Feb 2022 //
PRNEWSWIRE
TransThera announces collaboration with Roche to evaluate TT-00420
26 May 2021 //
PRNEWSWIRE
TransThera announces collaboration with Roche to evaluate TT-00420
26 May 2021 //
PRNEWSWIRE
TransThera announces collaboration with Roche to evaluate TT-00420
26 May 2021 //
PRNASIA
LG Chem Life Sciences & TransThera Announce FDA Clearance of IND for TT-01025
02 Dec 2020 //
CANOE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.